The Banqing Baidu Oral Solution Veterinary Grade API is handled as a concentrated stock solution before proportioning into nipple or bell drinkers for poultry and swine oral medication. The compounding vessel is a 316L stainless-steel tank of 500–1000 L working capacity fitted with a bottom-mounted agitator set to 300 rpm and a recirculation loop moving 1.0–1.5 m³/h. Purified water meeting USP <1231> limits is adjusted to 20–25°C; hard water with total hardness above 300 mg/L as CaCO₃ is pre-treated with citric acid monohydrate at 1.2 g/L to prevent cation-mediated precipitation of the API. Buffer salts, typically sodium citrate dihydrate at 0.25% w/v and citric acid monohydrate at 0.12% w/v, are dissolved first. The API is added through a 500 µm in-line screen under recirculation; dissolution is continued for 45 min, after which clarity is compared against Ph. Eur. 2.2.1 reference suspension II. The pH window is held at 5.2–6.5. Below 4.0 palatability rejection has been observed in broiler lines; above 7.0 oxidative degradation accelerates. Sodium benzoate 0.10% w/v and potassium sorbate 0.10% w/v are added as preservatives, and antimicrobial effectiveness is verified by USP <51> category IV criteria. Finished liquid is polished through a 5 µm polypropylene bag filter and then a 0.45 µm PVDF capsule before filling into 1 L amber HDPE bottles with LDPE dropper inserts. Terminal product light transmission is tested per USP <671> for translucent containers; bottle closure integrity is confirmed by vacuum decay per ASTM F2338-09.

The stock solution is proportioned into drinking lines using a solenoid-driven diaphragm pump calibrated to deliver 0.5–2.0% of the mainline flow. Final in-water concentration is derived from the approved species-specific dose, not from a universal fixed ratio. A field check using conductivity and pH is performed at the last nipple line; pH in the medicated water should remain between 5.5 and 7.0. Simultaneous administration of alkaline chlorination products or acidifiers outside this window is incompatible. Published data for this specific API when co-administered with quaternary ammonium disinfectants in the same waterline is limited; therefore, separate lines or flush cycles of 30 min with untreated water are required between operations.

What Limits Sterile Filtration Throughput for Injectable Veterinary Solutions?

The critical limit is bioburden prior to the sterilizing-grade filter. The bulk solution is prepared in a 316L jacketed vessel under 0.2 µm filtered nitrogen overlay at 15–25°C. Water for injection is used, with conductivity ≤1.3 µS/cm at 25°C per USP <645>, and dissolved oxygen is held below 0.5 mg/L by nitrogen sparging. The API is dissolved in 80% of the final volume; sodium chloride 0.45% w/v is added for isotonicity, and pH is adjusted to 6.0–7.0 with 0.1 N hydrochloric acid or sodium hydroxide. The solution is pre-filtered through a 0.45 µm PVDF membrane, then sterile-filtered through a 0.22 µm PVDF or PES membrane validated by ASTM F838-20 for bacterial retention. Pre-filtration bioburden must be below 10 CFU/100 mL by USP <61>, and endotoxin must be below 0.5 EU/mg by USP <85>. Filter throughput is modeled using Vmax; if a 0.22 µm cartridge shows flux decay below 70% of initial flow within the first 20 L/m² processed, the batch is suspended and the prefilter train is re-qualified because this indicates colloid loading from an improperly dispersed API lot.

Terminal sterilization is limited by the API thermal degradation profile. If forced degradation confirms that autoclaving at 121°C for 15 min produces total degradation products above 0.5% by peak area at HPLC, the process is switched to aseptic filtration followed by filling in an isolator classified as ISO 5. The final container is a 100 mL amber Type II glass vial with a chlorobutyl rubber stopper and an aluminum overseal. Headspace oxygen is reduced to ≤0.5% by nitrogen flushing before capping. Filled units are subjected to 100% visible particle inspection per USP <790>, and subvisible particulate matter must satisfy USP <788>: not more than 6000 particles ≥10 µm and 600 particles ≥25 µm per container. Sterility is tested by direct inoculation per USP <71>, and bacterial endotoxins by USP <85>. Residual solvent limits follow VICH GL18 for Class 2 solvents, and elemental impurities are controlled by USP <232> with analytical procedures per USP <233>. The formulation is incompatible with amine-based buffering agents if the API contains ester or lactone functionalities because amine nucleophiles can open these rings; published data for this specific API-amine interaction is limited.

Dry granulation is selected when the API exhibits hygroscopic weight gain above 2.0% at 60% RH within 24 h, because direct compression would cause sticking at compression speeds above 30 rpm on a 16-station rotary tablet press. The API is pre-blended with microcrystalline cellulose 102 at 55–65% w/w, crospovidone 5.0% w/w, colloidal silicon dioxide 0.5% w/w, and magnesium stearate 0.5% w/w in a 500 L V-blender for 15 min at 18 rpm. The blend is compacted on a roller compactor with 200 mm diameter rolls at a gap of 0.8–1.2 mm, hydraulic pressure 80–120 bar, and roll speed 3–5 rpm. Ribbons are milled through a 0.5–1.0 mm screen; the granulate fraction between 150 µm and 500 µm is retained for compression. Tablets are pressed at 8–12 kN compression force to a breaking force of 5–8 kp tested by USP <1217>. Tablet friability is controlled below 1.0% by USP <1216>, and disintegration must complete within 15 min in 0.1 N hydrochloric acid at 37°C by USP <701>. Uniformity of dosage units is evaluated by USP <905> with an acceptance value not more than 15.0.

Hard gelatin or HPMC capsules of size 3 are filled on a dosator-type capsule machine with fill weight 250 mg. Dissolution is tested by USP <711> Apparatus 1 at 100 rpm in 900 mL of 0.1 N HCl for immediate-release product. Moisture content is held below 2.0% by USP <921> Karl Fischer titration because sorbed water above this threshold reduces granule hardness and increases sticking. The terminal product is packed in 30-count HDPE bottles with 1 g silica gel canisters. Excipient compatibility is confirmed by DSC and HPLC after 14 days at 40°C/75% RH; any incompatibility with reducing sugars in mannitol-based diluents must be checked because Maillard-type degradation generates yellow chromophores in tablets containing the API at loadings above 20% w/w.

Wet Granulation Endpoint Control for Soluble-Granule Veterinary Dose Forms

For soluble granules intended for reconstitution into drinking water or oral drench, wet granulation is performed in a top-driven high-shear mixer with an impeller speed of 200 rpm and a chopper speed of 1500 rpm. The dry blend comprises the API at the labeled activity, lactose monohydrate 60–75% w/w, povidone K30 3–5% w/w, and croscarmellose sodium 2–4% w/w. Purified water is sprayed at 6–8% w/w of dry solids over 3–5 min; the endpoint is detected by a 30–40% rise in measured impeller torque relative to the dry phase rather than by fixed time. A granulation below the torque endpoint produces more than 25% fines, which segregate during sachet filling, while an over-wet granulation at water addition above 10% w/w forms oversized particles greater than 1.5 mm, which prolong reconstitution beyond 120 s in 1 L water at 25°C with 200 rpm stirring.

Wet granules are dried in a fluid bed dryer with inlet air temperature 55–65°C, product temperature 38–42°C, and air volume 1200–1500 m³/h. Drying is continued until loss on drying by USP <731> is below 2.0%. Dry granules are sized through a 1.0 mm sieve; laser diffraction per ISO 13320:2020 reports a median particle size D50 of 150–250 µm. The granules are filled into 10 g and 100 g triple-layer sachets of PET/aluminum/LDPE; seal strength is measured by ASTM F88/F88M-21 with a minimum seal force of 25 N/15 mm. Reconstituted solution is checked for clarity against Ph. Eur. 2.2.1 reference suspension II and for pH 5.0–6.5. Terminal microbial limits follow USP <61> and USP <62> for nonsterile oral aqueous products.

Feed Premix and Pellet Stability Parameters

In medicated feed premix production, the API is dispersed onto a carrier such as lactose monohydrate or dried wheat bran with moisture below 10%. A 1000 kg horizontal ribbon blender is filled to 60–70% of gross volume, and mixing proceeds at 20 rpm for 10 min after all components are charged. Homogeneity is tested by sampling 10 points from the discharged batch; the coefficient of variation for API content must be below 10% using the sampling and analytical scheme of Commission Regulation (EC) No 152/2009. The premix is then diluted into complete feed at a ratio determined by the approved dose; typical carrying ratios in swine and poultry are between 1:100 and 1:1000, but the exact figure is label-dependent. Batch-to-batch carryover is controlled by cleaning validation with a carryover limit below 2.5% of the lowest therapeutic dose, measured by HPLC with a limit of detection below 0.5 mg/kg feed.

Pellet stability depends on conditioning temperature and dwell time. When a steam conditioner is operated at 70°C with 30 s residence and a 3 mm die at compression ratio 1:8, post-pellet API retention is targeted at ≥95% of label claim. If the API is thermolabile, the premix is not added before conditioning; instead, a post-pelleting liquid spray or a cold-pellet process is used. Final medicated feed is assayed by HPLC method validation criteria per USP <621> for specificity and linearity; recovery at 80–120% of the labeled concentration is required at release. Combined with molasses-based binders above 3% w/w, high moisture granulation may reduce API stability if the active component is hydrolytically sensitive; published data for this specific API in molasses matrices is limited. Terminal product is packed in 20 kg multi-wall paper bags with a LDPE liner, and storage is controlled below 25°C and 60% RH.

When Oral Powder for Direct Administration Requires Electrostatic Charge Control

Oral powders for direct administration by dosing gun or top dressing require flow and dispersion control under low-humidity processing conditions. Dry powder is blended in a 500 L V-blender at 50% fill volume and 18 rpm for 15 min. To reduce electrostatic adhesion, hydrophobic fumed silica at 0.2% w/w is added after a 5 min pre-blend; this addition reduces Carr Index to ≤15 and angle of repose to ≤35° as characterized by USP <1174>. The powder is passed through a 250 µm screen before filling. Particle-size distribution is confirmed by laser diffraction per ISO 13320:2020 with D90 below 250 µm. Filled weight is controlled to ±2.5% on a volumetric auger filler; fill weight uniformity follows USP <905> for single-unit powder packages.

The terminal product is packaged in 10 g or 50 g heat-sealed sachets of paper/LDPE/aluminum/LDPE. Loss on drying by USP <731> is kept below 2.0%; at 65% RH or above, the material gains weight and electrostatic charging reverses polarity, causing segregation of fine API particles. The powder should not be compounded with mineral oil or other liquid binders unless a geometric dilution step of 1:1 API-to-carrier is performed first. Reconstitution in 1 L of drinking water at 25°C with 200 rpm stirring should produce a suspension or solution that passes a 250 µm screen within 60 s. Published data for this specific API’s zeta potential in tap water is limited; therefore, a pilot dispersion test with the intended field water source is required before bulk distribution.